Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.
endometrioid carcinoma
gene expression profiling
genomic
ovarian cancer
tissue microarray
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
25
05
2024
accepted:
28
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers. We collected clinical data and formalin-fixed paraffin-embedded (FFPE) samples for analysis at the DNA level using panel-based next-generation sequencing and array-comparative genomic hybridization. Additionally, we examined mRNA expression using NanoString nCounter® and protein expression through tissue microarray. We compared EOvC with other ovarian subtypes and uterine endometrioid tumors. Furthermore, we assessed the impact of molecular alterations on patient outcomes, including progression-free survival (PFS) and overall survival (OS). Preliminary analysis of clinical data from 668 patients, including 86 (12.9%) EOvC, revealed more favorable prognosis for EOvC compared with serous ovarian carcinoma (5-year OS of 60% versus 45%; P = 0.001) driven by diagnosis at an earlier stage. Immunohistochemistry and copy number alteration (CNA) profiles of 43 cases with clinical data and FFPE samples available indicated that EOvC protein expression and CNA profiles were more similar to endometrioid endometrial tumors than to serous ovarian carcinomas. EOvC exhibited specific alterations, such as lower rates of PTEN loss, mutations in DNA repair genes, and P53 abnormalities. Survival analysis showed that patients with tumors harboring loss of PTEN expression had worse outcomes (median PFS 19.6 months vs. not reached; P = 0.034). Gene expression profile analysis confirmed that EOvC differed from serous tumors. However, comparison to other rare subtypes of ovarian cancer suggested that the EOvC transcriptomic profile was close to that of ovarian clear cell carcinoma. Downregulation of genes involved in the PI3K pathway and DNA methylation was observed in EOvC. In conclusion, EOvC represents a distinct biological entity and should be regarded as such in the development of specific clinical approaches.
Identifiants
pubmed: 38923749
doi: 10.1002/1878-0261.13679
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : ARCAGY-GINECO
Organisme : ARARD (Association Regionale d'Assistance Respiratoire Domicile)
Informations de copyright
© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253.
Acién P, Velasco I, Acién M, Capello C, Vela P. Epithelial ovarian cancers and endometriosis. Gynecol Obstet Investig. 2015;79(2):126–135.
Fadare O, Parkash V. Pathology of endometrioid and clear cell carcinoma of the ovary. Surg Pathol Clin. 2019;12(2):529–564.
Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol. 2012;36(2):163–172.
De Nonneville A, Zemmour C, Frank S, Joly F, Ray‐Coquard I, Costaz H, et al. Clinicopathological characterization of a real‐world multicenter cohort of endometrioid ovarian carcinoma: analysis of the French national ESME‐Unicancer database. Gynecol Oncol. 2021;163(1):64–71.
Bouchard‐Fortier G, Panzarella T, Rosen B, Chapman W, Gien LT. Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow‐up. J Obstet Gynaecol Can. 2017;39(1):34–41.
Hollis RL, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat Commun. 2020;11(1):4995.
Mazina V, Devins K, Philp L, Bercow AS, James K, Bregar A, et al. Patterns of spread and genetic alterations of primary endometrioid carcinomas of the ovary. Int J Gynecol Cancer. 2023;33(9):1434–1439.
Hollis RL, Stanley B, Thomson JP, Churchman M, Croy I, Rye T, et al. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. NPJ Precis Oncol. 2021;5(1):47.
Birnbaum DJ, Sabatier R, Mamessier É, Birnbaum D, Bertucci F. An “ariditary” form of ovarian cancer. Med Sci (Paris). 2010;26(12):1040–1042.
Wiegand KC, Shah SP, Al‐Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis‐associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543.
Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228–231.
Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and loss of expression of ARID1A in uterine low‐grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625–632.
Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D. The ARID1A, p53 and ß‐catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium. PLoS One. 2018;13(2):e0192881.
Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–179.
Rambau PF, Duggan MA, Ghatage P, Warfa K, Steed H, Perrier R, et al. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype‐specific lynch syndrome screening in ovarian carcinomas. Histopathology. 2016;69(2):288–297.
Pal T, Permuth‐Wey J, Kumar A, Sellers TA. Systematic review and meta‐analysis of ovarian cancers: estimation of microsatellite‐high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res. 2008;14(21):6847–6854.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD‐1 blockade in tumors with mismatch‐repair deficiency. N Engl J Med. 2015;372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus‐Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair‐deficient cancer: results from the phase II KEYNOTE‐158 study. J Clin Oncol. 2019;8:1–10.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti‐programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair‐deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–1772.
Concin N, Matias‐Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39.
Oaknin A, Gladieff L, Martínez‐García J, Villacampa G, Takekuma M, De Giorgi U, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open‐label, phase 3 trial. Lancet. 2023;403:31–43.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145–2158.
Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res. 2023;29:4564–4574.
Nigon E, Lefeuvre‐Plesse C, Martinez A, Chauleur C, Lortholary A, Favier L, et al. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network. J Transl Med. 2023;21(1):408. https://doi.org/10.1186/s12967‐023‐04264‐7
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366.
Ida N, Nakamura K, Saijo M, Nasu A, Yoshino T, Masuyama H, et al. DNA mismatch repair deficiency and p53 abnormality are age‐related events in mixed endometrial carcinoma with a clear cell component. Pathol Res Pract. 2021;220:153383.
Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012;25(5):699–708.
Chung Y, Lee HW, Park JH, Yoo CH, Son BH, Kim K. Mutant pattern of p53 predicts local recurrence and poor survival rate in gastric cancer. Histol Histopathol. 2023;21:18596.
León‐Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of “multiple‐classifier” endometrial carcinomas. J Pathol. 2020;250(3):312–322.
de Nonneville A, Salas S, Bertucci F, Sobinoff AP, Adélaïde J, Guille A, et al. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT. EMBO Mol Med. 2022;14(10):e15859. https://doi.org/10.15252/emmm.202215859
Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, et al. Targeted NGS, array‐CGH, and patient‐derived tumor xenografts for precision medicine in advanced breast cancer: a single‐center prospective study. Oncotarget. 2016;7(48):79428–79441.
Network CGAR, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
Tsang HF, Xue VW, Koh SP, Chiu YM, Ng LPW, Wong SCC. NanoString, a novel digital color‐coded barcode technology: current and future applications in molecular diagnostics. Expert Rev Mol Diagn. 2017;17(1):95–103.
de Nonneville A, Finetti P, Birnbaum D, Mamessier E, Bertucci F. WEE1 dependency and pejorative prognostic value in triple‐negative breast cancer. Adv Sci (Weinh). 2021;8(17):e2101030.
de Nonneville A, Finetti P, Boudin L, Denicolaï E, Birnbaum D, Mamessier E, et al. Prognostic and predictive value of LIV1 expression in early breast cancer and by molecular subtype. Pharmaceutics. 2023;15(3):938.
de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, et al. A tyrosine kinase expression signature predicts the post‐operative clinical outcome in triple negative breast cancers. Cancers (Basel). 2019;11(8):1158.
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018;50(9):1262–1270.
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, et al. Prospective high‐throughput genome profiling of advanced cancers: results of the PERMED‐01 clinical trial. Genome Med. 2021;13(1):87.
Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget. 2016;7(19):27208–27219.
Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome‐wide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863–14868.
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678.
Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118–127.
Taminau J, Steenhoff D, Coletta A, Meganck S, Lazar C, de Schaetzen V, et al. inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expert‐curated datasets from GEO. Bioinformatics. 2011;27(22):3204–3205.
Winterhoff B, Hamidi H, Wang C, Kalli KR, Fridley BL, Dering J, et al. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecol Oncol. 2016;141(1):95–100.
Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:1–25.
Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9(7):811–818.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–5208.
Verhaak RGW, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high‐grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517–525.
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case‐control studies. Lancet Oncol. 2012;13(4):385–394.
Peres LC, Cushing‐Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1):60–68.
Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014;135(1):81–84.
Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review this article is a US government work and, as such, is in the public domain of The United States of America. Int J Cancer. 2011;129(8):1914–1922.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388:2159–2170. https://doi.org/10.1056/NEJMoa2302312
Zhang X, Wang A, Han L, Liang B, Allard G, Diver E, et al. PTEN deficiency in Tubo‐ovarian high‐grade serous carcinoma is associated with poor progression‐free survival and is mutually exclusive with CCNE1 amplification. Mod Pathol. 2023;36(5):100106.
Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, et al. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the ovarian tumour tissue analysis consortium. Br J Cancer. 2020;123(5):793–802.
Momeni‐Boroujeni A, Nguyen B, Vanderbilt CM, Ladanyi M, Abu‐Rustum NR, Aghajanian C, et al. Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol. 2022;35(9):1269–1278.
Fridley BL, Dai J, Raghavan R, Li Q, Winham SJ, Hou X, et al. Transcriptomic characterization of endometrioid, clear cell, and high‐grade serous epithelial ovarian carcinoma. Cancer Epidemiol Biomarkers Prev. 2018;27(9):1101–1109.
Worley MJ, Liu S, Hua Y, Kwok JSL, Samuel A, Hou L, et al. Molecular changes in endometriosis‐associated ovarian clear cell carcinoma. Eur J Cancer. 2015;51(13):1831–1842.
D'Alessandris N, Travaglino A, Santoro A, Arciuolo D, Scaglione G, Raffone A, et al. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: a quantitative systematic review. Gynecol Oncol. 2021;163(2):427–432.